Variables associated with high olanzapine dosing in a State Hospital

Journal of Clinical Psychiatry

Volumn 65, Issue 8, 2004, Pages 1138-1143

  Botts, Sheila ^a,b,d   Littrell, Robert ^b,d   De Leon, Jose ^a,b,c  

^a EASTERN STATE HOSPITAL   (United States)

^b University of Kentucky   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CYTOCHROME P450 1A2; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; AFFECTIVE PSYCHOSIS; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; DRUG UTILIZATION; FEMALE; HOSPITAL; HOSPITALIZATION; HUMAN; MALE; MENTAL HOSPITAL; METABOLISM; PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SEX DIFFERENCE; SMOKING; STATISTICS;

ADULT; AFFECTIVE DISORDERS, PSYCHOTIC; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COMORBIDITY; CYTOCHROME P-450 CYP1A2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; HOSPITALS, STATE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SEX FACTORS; SMOKING;

EID: 4544261414     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0817     Document Type: Article

References (34)

1. Lehman A, Steinwachs D. At issue: translating research into practice. The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998;24:1-10
2. Lehman A, Steinwachs D. Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull 1998;24:11-20 (Pubitemid 28128487)
3. Walkup JT, McAlpine DD, Olfson M, et al. Patients with schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry 2000;61: 344-348 (Pubitemid 30345935)
4. Segal S, Bola J, Watson M. Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services. Psychiatric Serv 1996;47:282-286 (Pubitemid 26074049)
5. Diaz FJ, de Leon J. Excessive antipsychotic dosing in two state hospitals. J Clin Psychiatry 2002;63:998-1003 (Pubitemid 35388058)
6. Reich J. Use of high-dose olanzapine in refractory psychosis [letter]. Am J Psychiatry 1999;156:661 (Pubitemid 29162996)
7. Lerner V. High-dose olanzapine for treatment-refractory schizophrenia. Clin Neuropharmacol 2003;26:58-61 (Pubitemid 36397360)
8. Sheitman BB, Lindgren JC, Early J, et al. High-dose olanzapine for treatment-refractory schizophrenia [letter]. Am J Psychiatry 1997;154: 1626 (Pubitemid 27471365)
9. Alao AO, Armenta WA, Yolles JC. High-dose olanzapine therapy in schizophrenia [letter]. Ann Pharmacother 1999;33:1228
10. Fanous A, Lindenmayer JP. Schizophrenia and schizoaffective disorder treated with high doses of olanzapine [letter]. J Clin Psychopharmacol 1999;19:275-276 (Pubitemid 29233025)
11. Mountjoy CQ, Baldacchino AM, Stubbs JH. British experience with high-dose olanzapine for treatment-refractory schizophrenia [letter]. Am J Psychiatry 1999;156:158-159 (Pubitemid 29034901)
12. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996;57(suppl 11):12-25 (Pubitemid 26389782)
13. de Leon J. Glucuronidation enzyme genes and psychiatry. Int J Neuropsychopharmacol 2003;6:57-72
14. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37:177-193 (Pubitemid 29452754)
15. Zyprexa [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2003
16. Haring C, Meise U, Humpel C, et al. Dose-related plasma levels of clozapine: influence of smoking behavior, sex and age. Psychopharmacology (Berl) 1989;99:S38-S40 (Pubitemid 19244137)
17. Ozdemir V, Kalow W, Posner P, et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady-state concentration in patients with schizophrenia. J Clin Psychopharmacol 2002;21:398-407 (Pubitemid 32673029)
18. Nakajima M, Yokoi T, Mizutani M, et al. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999;125:803-808 (Pubitemid 29192503)
19. Sachse C, Brockmoller J, Bauer S, et al. Functional significance of a C-A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. J Clin Pharmacol 1999;47:445-449 (Pubitemid 29161279)
20. Bender S, Eap CB. Very high cytochrome P4501A2 activity and nonresponse to clozapine [letter]. Arch Gen Psychiatry 1998;35:1048-1050 (Pubitemid 28506848)
21. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-258 (Pubitemid 27122521)
22. Tang B, Kalow W. Assays for CYP1A2 by testing in vivo metabolism of caffeine in humans. Methods Enzymol 1996;272:124-131 (Pubitemid 26299874)
23. Relling MV, Lin JS, Ayers GD, et al. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992;52:643-658 (Pubitemid 23001871)
24. Skogh E, Reis M, Dahl ML, et al. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 2002;24:518-526 (Pubitemid 34857906)
25. Norusis MJ. SPSS Professional Statistics 7.5. Chicago, Ill: SPSS Inc; 1997
26. Cohen J. A power primer. Psychol Bull 1992;112:155-159
27. Susce MT, Villanueva N, Diaz FJ, et al. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry. In press
28. de Leon J, Diaz FJ, Rogers T, et al. A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:165-171 (Pubitemid 36126659)
29. Linnet K, Olesen OV. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine co-medication. Ther Drug Monit 2002;24:512-517 (Pubitemid 34857905)
30. Markowitz JS, Devane CL, Liston HL, et al. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers. Clin Pharmacol Ther 2002;71:30-38 (Pubitemid 34124036)
31. Benowitz NL, Perez-Stable E, Fong I, et al. Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 1999;291:1196-1203
32. de Leon J, Diaz FJ, Rogers T, et al. Plasma cotinine, 3′-hydroxycotinine and their glucuronides in Caucasian and African American smokers [letter]. J Clin Psychopharmacol 2003;23:209-211 (Pubitemid 36368802)
33. Perez-Stable EJ, Herrera B, Jacob P, et al. Nicotine metabolism and intake in black and white smokers. JAMA 1997;280:152-156
34. Conley R, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155:914-920 (Pubitemid 28307603)